368 related articles for article (PubMed ID: 10452325)
21. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent.
Inoue T; Tomiyoshi K; Higuichi T; Ahmed K; Sarwar M; Aoyagi K; Amano S; Alyafei S; Zhang H; Endo K
J Nucl Med; 1998 Apr; 39(4):663-7. PubMed ID: 9544678
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
[TBL] [Abstract][Full Text] [Related]
24. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃.
Notni J; Pohle K; Wester HJ
Nucl Med Biol; 2013 Jan; 40(1):33-41. PubMed ID: 22995902
[TBL] [Abstract][Full Text] [Related]
25. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
[TBL] [Abstract][Full Text] [Related]
26. H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1?
Haubner R; Maschauer S; Einsiedel J; Eder IE; Rangger C; Gmeiner P; Virgolini IJ; Prante O
Biomed Res Int; 2014; 2014():243185. PubMed ID: 25374888
[TBL] [Abstract][Full Text] [Related]
27. Effects of insulinlike growth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice.
Sun BF; Kobayashi H; Le N; Yoo TM; Drumm D; Paik CH; McAfee JG; Carrasquillo JA
J Nucl Med; 2000 Feb; 41(2):318-26. PubMed ID: 10688118
[TBL] [Abstract][Full Text] [Related]
28. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of a peptide with affinity to head and neck cancer.
Nothelfer EM; Zitzmann-Kolbe S; Garcia-Boy R; Krämer S; Herold-Mende C; Altmann A; Eisenhut M; Mier W; Haberkorn U
J Nucl Med; 2009 Mar; 50(3):426-34. PubMed ID: 19223422
[TBL] [Abstract][Full Text] [Related]
30. Substituted halogenated arylsulfonamides: a new class of sigma receptor binding tumor imaging agents.
John CS; Lim BB; Vilner BJ; Geyer BC; Bowen WD
J Med Chem; 1998 Jul; 41(14):2445-50. PubMed ID: 9651150
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
Abdollahi A; Griggs DW; Zieher H; Roth A; Lipson KE; Saffrich R; Gröne HJ; Hallahan DE; Reisfeld RA; Debus J; Niethammer AG; Huber PE
Clin Cancer Res; 2005 Sep; 11(17):6270-9. PubMed ID: 16144931
[TBL] [Abstract][Full Text] [Related]
32. A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf==V-) is the potent inhibitor of angiogenesis.
Kawaguchi M; Hosotani R; Ohishi S; Fujii N; Tulachan SS; Koizumi M; Toyoda E; Masui T; Nakajima S; Tsuji S; Ida J; Fujimoto K; Wada M; Doi R; Imamura M
Biochem Biophys Res Commun; 2001 Nov; 288(3):711-7. PubMed ID: 11676501
[TBL] [Abstract][Full Text] [Related]
33. Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers.
Tateishi U; Oka T; Inoue T
Curr Med Chem; 2012; 19(20):3301-9. PubMed ID: 22664242
[TBL] [Abstract][Full Text] [Related]
34. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
35. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C
Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020
[TBL] [Abstract][Full Text] [Related]
36. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.
Dijkgraaf I; Kruijtzer JA; Liu S; Soede AC; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):267-73. PubMed ID: 16909226
[TBL] [Abstract][Full Text] [Related]
37. Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector.
Rogers BE; Curiel DT; Mayo MS; Laffoon KK; Bright SJ; Buchsbaum DJ
Cancer; 1997 Dec; 80(12 Suppl):2419-24. PubMed ID: 9406692
[TBL] [Abstract][Full Text] [Related]
38. Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells.
Lanza P; Felding-Habermann B; Ruggeri ZM; Zanetti M; Billetta R
Blood Cells Mol Dis; 1997 Aug; 23(2):230-41. PubMed ID: 9268674
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo evaluation of the effects of aluminum [¹⁸F]fluoride radiolabeling on an integrin αvβ₆-specific peptide.
Hausner SH; Bauer N; Sutcliffe JL
Nucl Med Biol; 2014 Jan; 41(1):43-50. PubMed ID: 24267053
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression.
Jia B; Shi J; Yang Z; Xu B; Liu Z; Zhao H; Liu S; Wang F
Bioconjug Chem; 2006; 17(4):1069-76. PubMed ID: 16848417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
